The clinical trial investigates the effects of choline supplementation on lipid metabolism in individuals at risk for Alzheimer's Disease (AD), particularly those carrying the APOE4 allele. Given the increasing prevalence of AD and the limited treatment options available, successful outcomes from this study could position choline as a novel dietary intervention in AD management. The market for AD therapeutics is substantial, with a growing demand for preventive strategies. Competitive analysis indicates that while several pharmaceutical agents target symptomatic relief, few focus on dietary supplements aimed at modifying disease progression. This trial could open avenues for partnerships with dietary supplement manufacturers and expand the therapeutic landscape for pre-symptomatic AD.